INTRODUCTION
Ghrelin is the only known peripherally produced and centrally active orexigenic hormone that is considered to be an important gut-brain signal for appetite control and energy balance. Its first recognised action was stimulation of growth hormone (GH) release from the pituitary gland but it also stimulates prolactin and ACTH and may inhibit LH/FSH. In addition to its orexigenic and pituitary activity, ghrelin acts on various systems, such as the gastrointestinal, cardiovascular, pulmonary, reproductive, and central nervous systems. The muscle effects of ghrelin involve stimulatory action on the cardiac muscle, vascular smooth muscle, ocular smooth muscle, gastrointestinal smooth muscle, and skeletal muscle and via the GH effect also on bone.
1,2 Ghrelin and its receptors are found in the reproductive organs and in the placenta, and during pregnancy and lactation ghrelin regulates maternal energy intake. 3 Furthermore, ghrelin could also act as a regulator of the gonadotropic axis. 4 It has recently been shown that ghrelin plays a role in the regulation of sodium reabsorption in the cortical collecting ducts of kidneys. 5 Ghrelin levels have been found to be altered in various conditions, examples of which are summarised in Table 1 . In this paper we focus on the role of ghrelin in obesity, Prader-Willi syndrome, anorexia and other eating disorders, and cachexia, as well as on the implications of ghrelin as a pharmacological target in relation to these disorders.
GHRELIN

Structure, receptor, and signalling pathway
Ghrelin is a 28-amino-acid peptide that is mainly produced by the neuroendocrine cells (named "X/A like" in rat and "P/D1" in humans) in the oxyntic mucosa of the gastric fundus. 19 Ghrelin is also produced in areas of the gastrointestinal tract and other peripheral organs but in lesser amounts. The 117-aminoacid preproghrelin protein is encoded by the human ghrelin gene on chromosome 3p25-26. Ghrelin is first cleaved from the preproghrelin polypeptide at the N-terminal by the prohormone convertase 1/3. An octanoic acid then esterifies a hydroxyl group of the third N-terminal amino-acid serine residue of the proghrelin peptide to form acyl ghrelin. demonstrated that the enzyme that attaches octanoate to serine-3 of ghrelin is GOAT (Ghrelin O-Acetyltransferase); this leads to the acylation of ghrelin which is required in order that ghrelin can bind to its receptor. 20 However, not all ghrelin is active acylated ghrelin; in fact, only a minority of the circulating ghrelin is acylated. Initially, it was thought that only acyl ghrelin activates the classical growth hormone secretagogue receptor (GHSR) expressing cells, whereas the nonmodified des-n-octanyl form of ghrelin (desacyl ghrelin) does not. 21 Meanwhile, although desacyl ghrelin was originally considered an inactive by-product of ghrelin secretion or degradation, recent evidence suggests that desacyl ghrelin acts in peripheral tissues and in the brain to regulate biological actions. A study by Heppner et al (2013) has shown that both acyl ghrelin and desacyl ghrelin significantly increased IP3 formation in HEK-293 cells transfected with human GHSR.
22 Intracerebroventricular (icv) infusion of desacyl ghrelin in mice increased fat mass at the highest dose tested, as well as glucose-stimulated insulin secretion. In contrast, icv desacyl ghrelin failed to regulate fat mass and induce hyperinsulinaemia in GHSR deficient (Ghsr -/-) mice. Desacyl ghrelin also failed to regulate these parameters in control mice when it was administered subcutaneously. Based on Table 1 . Disorders in which ghrelin alterations have been found. Green upward arrows indicate increased ghrelin levels, red downward arrows indicate decreased ghrelin levels. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] these findings, the authors suggested that desacyl ghrelin is an agonist of GHSR and regulates body adiposity and peripheral glucose metabolism through a CNS GHSR-dependent mechanism.
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GHSR has two variants: GHSR1a and GHSR1b. GHSR1a is able to bind acylated ghrelin, whereas GHSR1b is physiologically inactive, although one study suggested a dominant-negative, antagonistic role. 23 The results of this study showed that when the expression of GHSR1b exceeded that of GHSR1a, there was a decrease in the cell surface expression of GHSR1a with a consequent decrease in constitutive activation of phosphatidylinositol-specific phospholipase C. GHSR1a is a highly conserved G-protein coupled receptor and both GHSR1a and 1b have a wide expression in different tissues, with a role in various systems such as cardiovascular, immune, gastrointestinal, reproductive, and endocrine. GHSR1a is predominantly expressed in the pituitary and at much lower levels in the thyroid gland, pancreas, spleen, myocardium, and adrenal gland. 24 Interestingly, the locus of the GHSR gene has been implicated in the determination of height. 25 re 1. Simplified scheme showing that ghrelin stimulates the NPY/AGRP orexigenic pathway and inhibits the POMC-related anorectic pathway, resulting in increased food intake.
Feedback systems and appetite regulation
The first recognised effect of ghrelin was the induction of GH release from the somatotroph cells of the anterior pituitary. Moreover, by acting centrally or via vagal afferents, ghrelin can activate hypothalamic arcuate neurons that secrete the orexigenic peptides neuropeptide Y (NPY) and agouti-related peptide, and inhibit the anorexigenic neurons secreting -melanocyte-stimulating hormone ( -MSH). Arcuate neurons project to paraventricular, lateral hypothalamic, and other nuclei, as well as orexin in the lateral hypothalamus, which could contribute to the orexigenic effects of ghrelin. 26 Ghrelin is the first known peripheral hormone that can induce orexigenic effects through acting on hypothalamic pathways; moreover, it is active even with peripheral administration, in contrast to most orexigenic peptides which are only active when injected into the brain. Ghrelin is considered to be the peripheral counterpart of insulin and leptin, as it exerts opposite effects compared to these hormones ( Figure 1) . A study on healthy volunteers demonstrated that ghrelin reduces glucose-stimulated insulin secretion, leading to deterioration of glucose tolerance. 28 Moreover, the results of the CODING study demonstrated that a high circulating ghrelin level is associated with lower insulin resistance in the general population. 27 In addition, Tong et al showed that physiologic concentrations of exogenously infused ghrelin reduce insulin secretion without affecting insulin sensitivity in healthy humans, indicating that ghrelin antagonism could improve -cell function. 28 Tschop et al demonstrated that peripheral daily administration of ghrelin caused weight gain by reducing fat utilisation in mice and rats, this implying that ghrelin can induce an increase in adipose tissue and body weight. 29 Consistent with these results are the findings that ghrelin increases the mRNA expression of fat storage enzymes whilst decreasing the expression of the rate-limiting step in fat oxidation, carnitine palmitoyl transferase-1alpha. 30 These results may suggest that ghrelin induces a metabolic switch from the utilisation of fat to carbohydrates, whereas energy expenditure does not appear to be affected.
It has been proposed that ghrelin acts as an initiator signal for food consumption in humans: repeated plasma samples throughout a 24-h period demonstrated a clear preprandial rise and postprandial fall in plasma ghrelin levels, indicating that ghrelin can play a physiological role in meal inititation. 31 More recently an important interplay has been demonstrated between glucagon and ghrelin. The mechanisms by which glucagon induces satiety are not completely understood and it has been suggested that glucagon-induced reduction in total ghrelin exerted at the hypothalamo-pituitary level might be responsible for this effect.
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The role of ghrelin in reward-based eating GHSR1a is expressed in various nodes of the mesolimbic system, which include the ventral tegmental area (VTA) and the nucleus accumbens (NAc). More than 50% of dopaminergic VTA neurons co-express GHSR1a and are also present in GABAergic VTA neuronal subpopulations, which regulate the activity of the dopaminergic neurons. 33 It has been proposed that ghrelin can increase the dopaminergic transmission from VTA to the NAc, leading to augmentation of afferent reward signals. A recent study using a rat model demonstrated that VTA injections of ghrelin produced a significant increase in food motivation/ reward behaviour, as measured by sucrose-induced progressive ratio operant conditioning, and chow intake. Moreover, pretreatment with either a D1-like or D2 receptor antagonist into the NAc completely blocked the reward effect of ghrelin, leaving chow intake intact. 34 These results imply that the VTA to NAc dopaminergic projections, along with D1-like and D2 receptors in the NAc, are essential elements of the ghrelin responsive circuits controlling food reward behaviour.
Homeostatic feeding is thought to be under the control of circulating hormones acting primarily on the hypothalamus. The mechanisms by which ghrelin promotes food intake are not only homeostatic but also include enhancement of the rewarding effects of certain foods so that extra effort is made to obtain the pleasurable food, "hedonic feeding". 35 Hedonic feeding occurs in the absence of nutritional and caloric deficiency and can be described as "non-homeostatic". Functional magnetic resonance imaging (fMRI) following ghrelin administration demonstrated an increased neural response to food pictures in regions of the brain, including the amygdala, orbitofrontal cortex, anterior insula, and striatum, implicated in encoding the incentive value of food cues. 36 The effects of ghrelin on the amygdala and orbitofrontal cortex response were correlated with self-rated hunger ratings. 36 The results of this study suggest that metabolic signals such as ghrelin may favour food consumption by enhancing the hedonic and incentive responses to food-related cues.
Several studies have investigated the role of ghrelin in defining food preference. Ghrelin shifts food preference to diets rich in fat 29 or sweet food, regardless of whether the food has caloric content. Ghrelin increased the preference for 0.3% saccharin solution in wild type mice, while it did not have an effect in GHSR1 deficient mice, indicating that the ghrelin receptor pathway is necessary to mediate these phenomena. 37 In addition to enhancing preference for fatty and sweet foods, ghrelin also mediates more complex reward-based eating behaviours. Some studies have used the conditioned place preference test, which involves comparing the amount of time animals spend in an environment with which they preprogherin protein and the Arg51Gln variant at the end of mature ghrelin product (therefore possibly interfering with protein cleavage) has been studied in several cohorts, [44] [45] [46] but reproducible robust correlations were not found. The GHSR gene has also been studied in obese and diabetic populations 47, 48 with, however, no consistent results. Interestingly, the GHSR gene has been identified as factor in determining height. 25 Rare loss-of-function mutations have been identified in short children. Moreover, Pugliese-Pires et al reported inactivating mutations in the GHSR1 gene in patients with constitutional delay of growth and puberty. 49 The role of ghrelin in genetic obesity is an interesting question. Ablation of ghrelin in leptin-deficient ob/ob mice increases insulin secretion and improves hyperglycaemia. Surprisingly however, GHSR ablation worsened the hyperglycaemia, decreased insulin, and impaired glucose tolerance. 50 Five human homozygous leptin mutation patients and eight heterozygous carriers were studied for postprandial hormone changes. Plasma ghrelin levels in homozygotes remained remarkably unchanged following food consumption in contrast to a significant decline in heterozygous and normal subjects. 51 The effect of MC4R single nucleotide polymorphisms (SNPs) was examined in a large family study; to qualify for the study, families were required to have at least one overweight child between the ages of 4 and 19 years old. The results showed that genetic variation in MC4R plays a functional role in the regulation of physical activity, energy expenditure, and fasting serum ghrelin in Hispanic children; moreover, one of the SNPs (rs34114122) was selected as having likely functional effects on ghrelin, as Bayesian quantitative trait nucleotide analysis strongly supported a functional effect for rs34114122 on fasting serum ghrelin with a strong posterior probability (0.81). 52 A link has recently been identified between the obesity-related FTO gene and ghrelin. 53 The results demonstrated that the subjects homozygous for the FTO obesity-risk variant had dysregulated circulating levels of acyl ghrelin and attenuated postprandial appetite reduction; moreover, postprandial functional MRI showed that the same subjects had increased neuronal activity in brain regions controlling appetite, reward, and motivation after a test meal. The authors suggested that the have been conditioned to find a pleasurable diet to the time spent in a distinct environment associated with regular chow or no food. Another method that has been used is operant conditioning, for example operant lever pressing for high-rewarding foods. Studies have demonstrated that by using both the conditioned place preference test and operant conditioning, ghrelin enhanced the rewarding value of a high-fat diet when administered to ad lib-fed mice; by contrast, wild-type mice treated with ghrelin receptor antagonist and ghrelin receptor-null mice both failed to show conditioned place preference test to high-fat diet normally observed under calorie restriction. 38, 39 Furthermore, use of GHSR1 antagonists reduced operant responding for sucrose solution, as it was found that the intake and self-administration of sucrose in rats was reduced, as was also saccharin intake in mice. 40 
OBESITY
Various studies have demonstrated that plasma ghrelin levels in obese individuals are low and inversely proportional to body mass index. 41 Subjects with insulin resistance and high insulin levels also experience chronically low ghrelin levels. For example, a study analysing the fasting plasma ghrelin concentrations of 1,040 subjects demonstrated that ghrelin concentrations were negatively associated with fasting insulin and insulin resistance. 15 Ghrelin concentrations are also different in obese and normal-weight pre-pubertal children: in response to intake of a standardised breakfast, obese children showed an early recovery of postprandial ghrelin levels to baseline levels at 3 hours, while ghrelin levels remained suppressed after 3 hours in normal-weight children. 42 In addition to ghrelin levels being low in obese individuals, it has also been suggested that diet-induced obesity causes ghrelin resistance in NPY/AgRP neurons. Diet-induced obesity suppresses the neuroendocrine ghrelin system by decreasing acylated and total plasma ghrelin, decreasing ghrelin and GOAT mRNA in the stomach, decreasing expression of hypothalamic GHSR, and decreasing expression of Npy and Agrp mRNA. 43 It has been proposed that genetic polymorphisms of the ghrelin gene may play a role in the relationship of ghrelin and obesity. The Leu72Met change in the FTO genotype can alter the way the brain responds to circulating ghrelin. They moreover proposed a direct link between FTO risk alleles and ghrelin action, as it was found that FTO overexpression in cell-based assays increased ghrelin mRNA expression and total levels of active ghrelin compared with controls, whereas methylation of ghrelin mRNA was reduced. A prospective study used cross-sectional data from 985 elderly patients and demonstrated a positive relationship between the number of FTO C risk alleles (rs17817449) and plasma ghrelin levels; conversely, serum levels of the satiety-enhancing hormone leptin were inversely linked to the number of FTO C risk alleles. 54 These associations imply that FTO may facilitate weight gain in humans by shifting the endocrine balance from leptin towards ghrelin.
PRADER-WILLI SYNDROME
The Prader-Willi syndrome (PWS) is the most common cause of syndromic obesity, and results from paternally inherited genes in the q11-13 region of chromosome 15. 55 The SNORD116 locus lies in the 15q11-13 region of paternally expressed genes implicated in PWS and it has been proposed that lack of the paternal SNORD116 gene cluster has a determinant role in the pathogenesis of PWS. 56 It is characterised by initial poor feeding followed by hyperphagia from the age of 12 months leading to morbid obesity if uncontrolled. Despite their high BMI, several studies found high ghrelin levels in PWS adults and even more in children compared to normal subjects and BMI matched simple obese patients. [57] [58] [59] These studies might indicate that the hyperphagia observed in PWS could be secondary to elevated ghrelin levels. However, we need to keep in mind that PWS patients are not insulin resistant, rather they have increased insulin sensitivity. A more recent cross-sectional study measuring fasting plasma ghrelin levels in very young children with PWS (n=42) and controls (n=9) aged 7 months to 5 years found no hyperghrelinaemia in young children with PWS, and ghrelin changes were not associated with the timing of the transition to the characteristic hyperphagic phase. The authors suggested that abnormal and/or delayed development or sensitivity of the effector pathways of ghrelin (for example, parasympathetic and central nervous system) may interact with later hyperghrelinaemia to contribute to hyperphagia in PWS. 60 In regard to the studies demonstrating elevated ghrelin levels in PWS, several hypotheses have been put forward to account for these observations. 61 An increased number of ghrelin-producing cells in the gastric body and fundus of PWS patients could lead to elevated ghrelin levels. 62 Imprinting of paternal genes in region q11-13 on chromosome 15 may induce the production of excessive amounts of transcription factors that increase ghrelin expression. There could also be loss of a transcription inhibitory factor that normally suppresses ghrelin expression. 63 Reduced visceral adiposity and relative hypoinsulinaemia could partially explain hyperghrelinaemia in PWS. 64 Abnormal parasympahetic vagal innervation of the stomach and abnormal sympathetic tone in PWS patients might also explain the high ghrelin levels. 65 Moreover, a study has shown that ghrelin dysregulation in PWS occurred very early and preceded the onset of obesity, indicating that in the first years of life, hyperghrelinaemia in PWS may be a response to failure to thrive or food restriction. 66 The lack of ghrelin suppression after meals in PWS adults 59 but not in PWS children 67 may imply that the progressive deterioration of PWS could result in a multistep developmentally driven process in ghrelin dysregulation. Also, in adults with PWS, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. A study by Purtell et al points to the fact that compared to adiposity-matched control subjects, hyperphagia in PWS is not related to a lower postprandial GLP-1 or PYY response and that elevated ghrelin levels in PWS are consistent with increased hunger and are unrelated to insulin levels. 68 
EATING DISORDERS
Anorexia nervosa
Anorexia nervosa (AN) is the most common cause of weight loss in young women and of admission to child and adolescent services. 69 Moreover, anorexia nervosa has the highest mortality of any psychiatric disorder. 70 It is characterised by refusal to maintain body weight at or above minimally normal weight, intense fear of gaining weight or becoming fat, and disturbance in the way body weight or shape is ex-perienced. The aetiology of anorexia nervosa is not currently well understood. Recently, some studies have focused on the relationship between hunger regulation and gut-brain peptides; in particular, numerous data show that alterations of central and/or peripheral peptidergic signalling are related to disturbed regulation of feeding and body weight, peptidergic signalling including anorexigenic corticotropic-releasing factor, melanocortin, NPY, and ghrelin.
In terms of ghrelin levels, several studies have reported that individuals with anorexia nervosa have higher levels of fasting plasma ghrelin than normal weight healthy controls. For example, Monteleone et al compared 20 female anorexia nervosa patients with 20 healthy women; it was found that AN patients displayed significantly increased circulating levels of ghrelin compared to healthy patients. 71 In another study, Nedvikova et al investigated responses of plasma ghrelin to food intake, meal volume, and meal nutritional value in healthy volunteers and women with anorexia nervosa; it was found that fasting plasma ghrelin was significantly higher in AN patients than in controls and correlated negatively with percentage of body fat in both groups. Ghrelin levels markedly fell after consumption of either a standardised meal or fibre in controls, but not in anorexic women. 72 These results indicate that the acute plasma ghrelin response to food intake is impaired in AN patients. The authors suggested that this response could be part of a chronic adaptation to prolonged food restriction which attempts to restore normal feeding conduct by maintaining the drive to eat. Another study by Tolle et al involved assessing ghrelin plasma levels in anorexia nervosa patients before and after re-nutrition and in constitutionally thin subjects with BMIs equivalent to those of AN women but with no abnormal feeding behaviour. 73 It was found that morning fasting plasma ghrelin levels were doubled compared with levels in controls and constitutionally thin subjects and that 4-and 24-hour ghrelin levels were increased compared to controls. These results indicate that ghrelin levels are not only dependent on body fat mass but are also affected by nutritional status.
The reduced food intake that characterises anorexia nervosa, despite the chronically increased ghrelin levels, may suggest that this condition represents a state of "ghrelin insensitivity or resistance". This theory is supported by results that showed that anorexia nervosa patients did not respond to ghrelin administration by increasing appetite and food intake as did healthy controls. 74 Ogiso et al comment that although many studies have investigated the association between anorexia nervosa and ghrelin, most studies measured total ghrelin and did not distinguish between acyl ghrelin and desacyl ghrelin. 26 This could play a role as to how results are interpreted, as certain studies have found that desacyl ghrelin has opposite effects to acyl ghrelin. For example, Asakawa et al demonstrated that desacyl ghrelin induces a negative energy balance by decreasing food intake and delaying gastric emptying in mice. 75 The results of these studies contradict the previously mentioned findings of Heppner et al according to which desacyl ghrelin is an agonist of GHSR leading to increased fat mass and increased glucose-stimulated insulin secretion.
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In a study by Koyama et al, the changes in ghrelin levels (both acyl and desacyl) during early treatment of anorexia nervosa were measured. 76 It was found that desacyl ghrelin in anorexia nervosa patients was higher than in control subjects before the therapy, but it decreased with treatment and was significantly lower than in control subjects after 8 weeks of treatment; moreover, the ratio of the acyl ghrelin to total ghrelin increased with 8 weeks' treatment. These results may suggest that a successful refeeding outcome could involve increasing acyl ghrelin and decreasing desacyl ghrelin. In conclusion, future studies investigating ghrelin levels in anorexia nervosa could measure both acyl and desacyl ghrelin in order to obtain a clearer picture of the role of ghrelin in anorexia nervosa.
It currently remains unknown why ghrelin levels are higher in anorexia nervosa patients than in healthy controls and why people with anorexia nervosa do not respond appropriately to ghrelin. Terashi et al proposed that changes of ghrelin reactive autoantibodies could explain elevated plasma ghrelin in AN. 77 Autoantibodies to ghrelin occur naturally, and it is thought that physiologic ghrelin autoantibodies help regulate the ghrelin plasma levels. 41 The autoantibodies could alter the feeding-regulatory circuitry and behaviour by changing the signalling of the molecule, ranging from transport to neutralisation. 26 In their study, Terashi et al found that patients with anorexia nervosa had significantly lower plasma levels of acyl ghrelin IgG, IgM, and IgA autoantibodies; the levels remained low even after one month of refeeding. 77 The authors proposed that the decrease of bioavailable ghrelin autoantibodies may underlie a long-term elevation of plasma ghrelin levels and the resulting phenomenon of ghrelin resistance in malnourished patients with anorexia nervosa.
Differences in ghrelin levels have also been noted in regard to the type of anorexia nervosa. Whereas studies have recorded increased ghrelin levels in restrictive anorexia nervosa, others have reported unchanged ghrelin levels in binge-purge anorexia nervosa. 78, 79 Further research is needed to fully elucidate the ghrelin effects and the ghrelin level fluctuations in anorexia nervosa. In addition, further investigations are required to determine whether any genes for ghrelin can predispose individuals to anorexia nervosa. It has been hypothesised by Dardennes et al (2007) that ghrelin and AgRP polymorphisms confer susceptibility to anorexia nervosa; the results of their study demonstrated a transmission disequilibrium for the Leu72Met variant of the preproghrelin gene and an excess of transmission of the Gln90Leu72 preproghrelin/ obestatin haplotype in patients with anorexia nervosa (bingeing-purging subtype). 80 Moreover, Muller et al observed an association of a GOAT gene variant with AN in a study involving 543 German patients with AN and 612 German normal and underweight healthy controls. 81 A genetic variation of the ghrelin activator gene MBOAT4 was implicated as a causal factor in anorexia nervosa, 81 and the 3056T>C SNP of the ghrelin gene was suggested in another as being related to recovery from restrictive anorexia nervosa. 82 However, Kindler et al found no increased occurrence of 3 ghrelin gene polymorphisms in patients with eating disorders compared with in healthy controls. 83 
Bulimia nervosa
Bulimia nervosa (BN) is characterised by eating in a discrete period of time an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances. In addition, a sense of lack of control over eating during the episode and recurrent inappropriate compensatory behaviour to prevent weight gain characterise the syndrome. 84 Ghrelin levels in bulimia nervosa are variable according to the clinical study and various results have been obtained. BMI matched bulimia nervosa patients had significantly higher fasting plasma ghrelin levels compared to healthy volunteers. 85, 86 However, other studies found no significant differences. 71, 87 It has been suggested that the differences in the results of these studies could be attributed to the different methods being used, for example radioimmunoassay vs. ELISA, or measuring fasting vs non-fasting ghrelin levels. 88 Reduced ghrelin suppression after eating was found in some studies and it has been theorised that this blunted postprandial decrease in ghrelin levels could indicate a reduced satiety response, which could in turn explain the binges. 86, 89 When comparing bulimia nervosa with anorexia nervosa patients, fasting plasma ghrelin levels were found to be significantly lower in women with bingeeating and purging behaviour compared to restricting type anorexia nervosa patients. 90 It is possible that ghrelin gene polymorphisms could be associated with vulnerability for bulimia nervosa. For example, it has been found that the C allele at the 3056T>C SNP (CC and TC genotypes) in intron 3 and the Met allele at the Leu72Met SNP of the ghrelin gene were significantly more frequent in purging-type BN. 82 Moreover, a GHSR gene variant that was associated with BN in Japanese patients.
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CACHEXIA
Cachexia is defined as a complex metabolic syndrome associated with underlying illness and characterised by loss of muscle with or without loss of fat mass. 92 Cachexia is distinct from starvation, agerelated loss of muscle mass, primary depression, malabsorption, and hyperthyroidism and is associated with increased morbidity. It can occur in patients with advanced cancer and/or chronic progressive diseases. 93 Malnutrition has been observed in a variety of patients with chronic diseases, including congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), renal failure, and cancer. 94 The inverse relationship between plasma ghrelin and BMI observed in healthy individuals also applies to cachectic patients, for example in underweight patients with chronic obstructive pulmonary disease, 95 but there were no significant differences in ghrelin levels between normal subjects and cachectic (CHF, COPD, cancer) patients after matching for BMI. 95, 96 Some studies, however, have demonstrated elevated levels in cachectic patients with a variety of cancers. 97 These elevated ghrelin levels could serve as a compensation for energy loss to maintain homeostasis and as a defence mechanism against starvation. Various factors could contribute to the increased ghrelin levels in certain cancers, and it has been reported that some cancers can express ghrelin. 98 Elevated ghrelin levels have also been found in cachectic patients with chronic renal failure, 99 but this might be due to increased desacyl ghrelin levels, whereas acyl ghrelin levels are not increased. 100 It was suggested that the elevation in total ghrelin is secondary to the fact that desacyl ghrelin is cleared through the kidneys, leading to accumulation in renal insufficiency.
41
APPLICATIONS IN CLINICAL PRACTICE
Ghrelin as a pharmacotherapy
Ghrelin administration
In addition to lean and obese healthy volunteers, ghrelin administration studies have involved several patient populations including those with congestive heart failure, several types of cancer, diabetes mellitus, pulmonary disease, anorexia nervosa, end-stage renal disease, Cushing's syndrome, gastroparesis, polycystic ovary syndrome, hyperthyroidism, hyperparathyroidism, depression, acromegaly, and GH deficiency. 101 By reviewing these treatment studies Garin et al concluded that there is strong evidence that ghrelin is an effective appetite stimulant, resulting in increased energy intake but that there is less evidence that ghrelin can cause positive changes in body composition, and almost no evidence of an increase in muscle strength and performance. 101 Only a small number of studies have so far investigated the effects of ghrelin administration on patients with anorexia nervosa. The first study to investigate this, by Broglio et al, involved administration of ghrelin to nine women with anorexia nervosa (restricting type) and seven healthy women; the results indicated an impaired GH response to ghrelin in anorexia nervosa. Although food intake was not measured, hunger was mentioned as an adverse event. 102 A more recent pilot study by Hotta et al investigated the effects of ghrelin on appetite, energy intake, and nutritional parameters in five patients with restricting-type AN who were fully motivated to gain body weight but could not increase their food intake because of malnutrition-induced gastrointestinal dysfunction. The daily energy intake of the five patients during the pre-treatment period ranged from 825 to 1426 kcal. During ghrelin infusion, four patients showed a statistically significant increase in daily energy intake. Mean increase in daily energy intake during ghrelin infusion was about 20% when compared with the pretreatment period. Analysis of nutrients revealed significant increases in daily intakes of carbohydrate in three patients, fat in one patient, and protein in all patients. The ghrelin administration improved epigastric discomfort and constipation and increased the hunger score. 103 The results of these studies indicate that ghrelin could potentially be a new treatment for anorexia nervosa. However, a study by Miljic et al found that ghrelin administration did not significantly affect appetite in 25 young women with anorexia nervosa. 74 It has been suggested that these results could be reflecting differences in population, treatment duration, and dose. 89 Other studies investigated the effect of ghrelin administration on various cachectic conditions. Nagaya et al administered human synthetic ghrelin intravenously to 10 patients with congestive heart failure for three weeks. It was found that both food intake and body weight were increased; moreover, exercise capacity, muscle wasting, and left ventricular function were improved. 104 An open label pilot study by Nagaya et al examined whether ghrelin could improve cachexia and functional capacity in seven cachectic patients with COPD. It was found that a three-week ghrelin treatment resulted in a significant increase in mean body weight, food intake, lean body mass, and peripheral and respiratory muscle strength; moreover, ghrelin attenuated the exaggerated sympathetic nerve activity. 105 In a study by Wynne et al, nine peritoneal dialysis patients with mild to moderate malnutrition were administered ghrelin subcutaneously. The results demonstrated a significant increase in the group mean absolute energy intake, compared with placebo; moreover, ghrelin administration resulted in immediate doubling of energy intake when expressed as proportional energy increase for each individual. 106 Other studies investigated the effects of administering ghrelin in the setting of cancer cachexia. Although the use of supra-physiological doses of ghrelin was generally required, the effects on appetite have been positive; this suggests that the effects of ghrelin on appetite-stimulating centres are not saturated in the setting of cancer cachexia. A randomised, placebo-controlled, cross-over clinical trial demonstrated appetite stimulation by ghrelin in seven cancer patients with cachexia; the results showed that administration of ghrelin significantly increased food intake and meal appreciation as compared to saline infusion. 107 However, there are concerns regarding the use of ghrelin in cancer cachexia; for example, an important concern is that ghrelin may increase growth factors, such as GH and IGF-1, leading to stimulation of tumour growth. 108 In addition, the short half-life of ghrelin and the route of delivery via injection are additional limitations of the use of ghrelin as a therapeutic agent.
Apart from exerting anti-cachectic effects by acting on the GHSR1a receptor, Porporato et al proposed that acyl and desacyl ghrelin could act on a common, unidentified receptor to block skeletal muscle atrophy in a GH-independent manner. 109 Their results demonstrated that both acyl and desacyl ghrelin inhibited dexamethasone-induced skeletal muscle atrophy and atrogene expression through PI3K -, mTORC2-, and p38-mediated pathways in myotubes. Moreover, it was shown that acyl and desacyl ghrelin induced phosphorylation of Akt in skeletal muscle and impaired fasting-induced atrophy in Ghsr-deficient mice.
A recent double-blind placebo, controlled, crossover study has indicated that desacyl ghrelin may improve glycaemic control in obese diabetic subjects by decreasing acylated ghrelin level. 110 The study involved investigating the effects of continuous overnight infusion of desacyl ghrelin on acylated ghrelin levels and glucose and insulin responses to a standard breakfast meal in eight overweight patients with type 2 diabetes. It was found that, compared with placebo, overnight desacyl administration significantly decreased postprandial glucose levels, both during continuous glucose monitoring and in peak serum glucose levels; moreover, the degree of improvement in glycaemia was correlated with baseline plasma acylated ghrelin levels, which were decreased. The authors of the study suggested that desacyl ghrelin is a good candidate for the development of compounds in the treatment of metabolic disorders and conditions such as type 2 diabetes mellitus and PWS.
The administration of desacyl ghrelin may also have a clinical application. It has previously been demonstrated that desacyl ghrelin can counteract the effects of acyl ghrelin on insulin secretion and glucose metabolism: acyl ghrelin administration was followed by a decrease in insulin levels and an increase in plasma glucose levels; while desacyl ghrelin administration alone had no effects, desacyl ghrelin together with acyl ghrelin diminished the insulin and glucose response to acyl ghrelin. 111 Moreover, it has been reported that i.v. desacyl ghrelin administration improves glucose metabolism and inhibits lipolysis in healthy volunteers. 112 The results of these studies imply that desacyl ghrelin or desacyl ghrelin analogs might have a pharmacological application in the future treatment of metabolic disorders, diabetes, obesity, and PWS, as they could inhibit or suppress ghrelin.
Ghrelin receptor agonists
Several ghrelin agonists are currently under development for various indications. For example, a recent phase 2a, randomised, double-blind 28-day study of the ghrelin receptor TZP-102 demonstrated a reduction of the symptoms of diabetic gastroparesis. 113 Other targets of ghrelin receptor agonists include cancer cachexia, postoperative ileus, and opioid-induced bowel dysfunction. 114 Palus et al used a rat model of congestive heart failure to investigate the effects of administering the ghrelin analogues BIM-28125 and BIM-28131; whereas placebo-treated rats gained no fat (but only lean mass), the active compounds induced both fat and lean mass gain. 115 In a recent study, Lenk et al also used a rat model of congestive heart failure and showed that the same analogues significantly increased the expression of myostatin in the skeletal muscles of the rats. 116 In a human study of healthy volunteers, the oral ghrelin agonist and GH secretagogue RC-1291 produced dose-related increases in body weight with no dose-limiting adverse effects; the authors suggested that RC-1291 could be an effective treatment for cancer-associated cachexia and anorexia.
Ghrelin receptor antagonists
Various pharmacological tools are being investigated to counteract the effects of ghrelin (Figure 2 ). The ghrelin receptor antagonists are an example of these tools. A study by Beck et al involved administering the ghrelin receptor antagonist [D-Lys)]-GHRP-6 to fa/ fa obese Zucker rats; it was found that the antagonist decreased the food intake of rats. 118 Moreover, this antagonist decreased energy intake, rate of gastric emptying, and body weight gain in ob/ob mice. 119 Esler et al also showed that the ghrelin antagonist YIL-781 not only reduced fat mass in a mouse model of diet-induced obesity but also directly improved glucose homeostasis by enhancing glucose-stimulated insulin secretion. 120 Several compounds have been identified as ghrelin receptor antagonists, including piperidine-substituted quinazolinone derivatives, optimised piperazine-bisamide analogs, and carbohydrazide derivatives. These classes of GHSR1a antagonists could become pharmacological tools for the treatment of obesity, as well as type 2 diabetes and metabolic syndrome. However, long-term human and animal studies are still required to further investigate the beneficial effects of ghrelin antagonists in the context of obesity.
Ghrelin receptor inverse agonists
The ghrelin receptor GHSR1a has a high constitutive activity. It has been proposed that inverse ghrelin receptor agonists could be useful for treating obesity by decreasing this constitutive activity. 121 Moreover, it has been hypothesised that the constitutive activity of the receptor may be high between meals, when plasma ghrelin levels are low; hence, it has been suggested that whereas ghrelin receptor antagonists could be used to block the acute preprandial ghrelin signal, inverse ghrelin agonists could block the high constitutive activity. 114 The compound [D-Arg1, D-Phe5, D-Trp7,9,Leu11] Substance P was identified as a a low-potency antagonist but a high-potency full inverse agonist on the ghrelin receptor. 122 Long-term animal and human studies are necessary to elucidate the beneficial effects of ghrelin receptor inverse agonists in the treatment of obesity.
Ghrelin O-acyltransferase (GOAT) inhibitors
Pharmacological tools have been developed to target the inhibition of GOAT. An example of these is GO-CoA-Tat, which is a peptide-based bisubstrate analog. Barnett et al demonstrated that GO-CoA-Tat potently inhibits GOAT in vitro, in cultured cells, and in mice. 123 Moreover, they showed that intraperitoneal administration of GO-CoA-Tat improved glucose tolerance and reduced weight gain in wild-type mice re 2. Diagram demonstrating pharmacological tools to enhance or counteract the effects of ghrelin. Synthesis of ghrelin and acylation by GOAT occur in the endoplasmic reticulum. Both acyl and desacyl ghrelin are then secreted into the bloodstream by fusion of secretory vesicles with the plasma membrane. Acyl ghrelin then activates GHSR1a receptors T2R, bitter taste receptor.
but not in ghrelin-deficient mice. These results indicate that GOAT could be a promising target for the development of anti-obesity and anti-diabetes drugs. In terms of future design of GOAT inhibitors, the results of suggest that GOAT is subjected to end-product inhibition and this inhibition is better achieved with substrates having the octanoyl group attached through an amide linkage rather than the corresponding ester. 124 
Bitter taste receptors
Bitter taste receptors (T2R) and the gustatory G proteins, -gustducin (gust) and -transducin, are expressed in the gut and are involved in the chemosensation of nutrients. Jannsen et al (2011) demonstrated that intragastric administration of T2R-agonists increased food intake during the first 30 min in wildtype but not in gust / and ghrelin receptor knockout mice. 125 Moreover, gavage of T2R-agonists increased plasma octanoyl ghrelin levels in wild-type mice but the effect was partially blunted in gust / mice. The results of this study suggest that activation of bitter taste receptors stimulates ghrelin secretion, meaning that T2R could be a new pharmacological target for the modulation of ghrelin levels.
Octreotide
Octreotide is a somatostatin receptor type 2 agonist that is used to treat patients with acromegaly or neuroendocrine tumours. Known side-effects of octreotide include decreased insulin secretion, which can lead to impaired glucose tolerance. Norrelund et al (2002) showed that somatostatin infusion lowered ghrelin levels by 70-80% in healthy volunteers. 126 In a pilot study by Haqq et al (2003b), short-term octreotide treatment markedly decreased fasting ghrelin concentrations in children with PWS but did not fully ablate the normal meal-related suppression of ghrelin.
127 A 56-week prospective, randomised, cross-over trial by De Waele et al (2008) evaluated whether long-acting octreotide decreases acylated and desacyl ghrelin concentrations, body mass, appetite, and compulsive behaviour towards food in adolescents with PWS. 128 It was found that octreotide treatment caused a prolonged decrease in ghrelin concentrations in adolescents with PWS but did not improve body mass, appetite or compulsive foodtaking behaviour. Based on this evidence, octreotide cannot be currently recommended for the treatment of PWS. 128 The authors proposed several possible explanations for these findings. For example, the decrease in circulating ghrelin may be too small to be perceived at the hypothalamic level and translate to clinically-relevant effects, or octreotide may blunt the postprandial decrease in ghrelin concentrations.
Rikkunshito: a ghrelin enhancer
Rikkunshito is a kampo herbal medicine which is widely used in Japan for the treatment of upper gastrointestinal symptoms. 129 A study by Matsumura et al (2010) involved administering rikkunshito to healthy volunteers and mice for two weeks and examining the changes in plasma peptide and hormone levels; it was found that rikkunshito increased the plasma acylated ghrelin level in both healthy volunteers and normal mice. 130 Apart from stimulating the secretion of ghrelin, rikkunshito can enhance ghrelin's orexigenic effect by several additional mechanisms; for example, it has been found that rikkunshito increased the reactivity of ghrelin by inhibiting PDE3 activity. 131 Examples of indications where rikkunshito use could be beneficial include cisplatin-induced anorexia, anorexia of aging, and stress-related increased or decreased food intake.
Neutralisation of ghrelin
Anti-ghrelin vaccine
Vaccination against ghrelin could be another strategy to block the effects of ghrelin. Active vaccination of mature rats with ghrelin immunoconjugates led to the production of antibodies directed against acylated ghrelin; the antibody production decreased feed efficiency, relative adiposity, and body weight gain. 132 In a study involving normal weight mice and mice with diet-induced obesity, vaccination was shown to be effective in decreasing acute food intake and increasing energy expenditure, but there was no change in body weight over the study span. 133 In another study, high-affinity anti-acyl ghrelin-specific monoclonal antibodies were generated; although in a 4-week chronic study the antibodies effectively bound to endogenous acyl ghrelin, long-term administration did not affect food intake or body weight gain in a mouse model of diet-induced obesity. 134 Moreover, the development of a ghrelin vaccine in Switzerland has been stopped because of obtaining negative phase IIa results in a study with 111 obese subjects; strong antibody responses to ghrelin were elicited leading to reduced hunger, but there was no significant weight loss. 135 The results of these studies suggest that although peripheral neutralisation of ghrelin can suppress appetite stimulated by a transient ghrelin surge, compensatory mechanisms contributing to the regulation of energy balance may prevent long-term effects on body weight. Patients that could benefit by an effective anti-ghrelin vaccine could include individuals with PWS. In obesity, most obese individuals have low ghrelin levels and the vaccine may not be effective on its own for this patient group; instead, an anti-ghrelin vaccine could benefit obese patients enrolling in a diet and exercise program as adjuvant therapy for weight loss and bodyweight control. 136 
Spiegelmers
RNA spiegelmers, meaning "RNA mirrors", are a novel type of ghrelin blocking reagents. Spiegelmers are oligonucleotides synthesised with unnatural L-enantiomers of ribose in the sugar-phosphate backbone, making them stable in vivo. They have been designed to bind specifically and avidly to acylated ghrelin, thus preventing activation of the ghrelin receptor in vitro. 114 The spiegelmer NOX-B11-2 blocked ghrelin mediated activation of GH secretagogue receptor 1a in cell culture and also effectively promoted weight loss in diet-induced obese mice. 137 Another spiegelmer, NOX-B11-3, effectively blocked the excitatory effect of ghrelin in the medial arcuate nucleus of rats. 138 Moreover, i.v. administration of the spiegelmer NOX-B11 efficiently suppressed ghrelininduced growth hormone release in rats. 139 Further investigation is required to elucidate the beneficial clinical effects of spiegelmers, which could be useful to treat diseases with high ghrelin levels and/or severe obesity, such as PWS.
CONCLUSION
Present evidence suggests that ghrelin plays an important role in obesity and eating disorders, as well as in regulating appetite and energy balance in healthy individuals. The effects of ghrelin can be both homeostatic (under the control of circulating hormones acting primarily on the hypothalamus), as well as non-homeostatic involving control of rewardbased eating. In pathological states, ghrelin can be lower than normal, as is seen in obese individuals, or can be higher than normal, as has been reported for PWS, anorexia nervosa, bulimia nervosa, and certain types of cachexia.
In the future, the use of ghrelin as a clinical target seems promising. This could involve the use of pharmacotherapies (such as ghrelin administration, ghrelin agonists/antagonists/inverse agonists, GOAT inhibitors), as well as neutralisation of ghrelin (for example, by vaccines and spiegelmers). Further studies and large clinical trials are necessary to fully determine the role that ghrelin can play in future clinical practice.
